Achillion Pharmaceuticals Company Profile (NASDAQ:ACHN)

About Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ACHN
  • CUSIP: 00448Q20
  • Web:
  • Market Cap: $566.03 million
  • Outstanding Shares: 136,723,000
Average Prices:
  • 50 Day Moving Avg: $3.73
  • 200 Day Moving Avg: $4.08
  • 52 Week Range: $3.15 - $10.06
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -69.00
  • P/E Growth: -0.390
Sales & Book Value:
  • Annual Revenue: $15 million
  • Price / Sales: 37.74
  • Book Value: $2.80 per share
  • Price / Book: 1.48
  • EBIDTA: ($66,230,000.00)
  • Return on Equity: -9.46%
  • Return on Assets: -9.16%
  • Current Ratio: 29.93%
  • Quick Ratio: 29.93%
  • Average Volume: 1.41 million shs.
  • Beta: 1.59
  • Short Ratio: 7.2

Frequently Asked Questions for Achillion Pharmaceuticals (NASDAQ:ACHN)

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings results on Thursday, May, 4th. The company reported ($0.15) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.16) by $0.01. During the same period last year, the firm earned ($0.13) EPS. View Achillion Pharmaceuticals' Earnings History.

When will Achillion Pharmaceuticals make its next earnings announcement?

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Achillion Pharmaceuticals.

What guidance has Achillion Pharmaceuticals issued on next quarter's earnings?

Achillion Pharmaceuticals issued an update on its FY17 earnings guidance on Thursday, February, 23rd. The company provided earnings per share (EPS) guidance of -$0.75 to -$0.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.48).

Where is Achillion Pharmaceuticals' stock going? Where will Achillion Pharmaceuticals' stock price be in 2017?

9 brokerages have issued 1 year price targets for Achillion Pharmaceuticals' shares. Their predictions range from $5.00 to $16.00. On average, they expect Achillion Pharmaceuticals' share price to reach $9.75 in the next year. View Analyst Ratings for Achillion Pharmaceuticals.

Are investors shorting Achillion Pharmaceuticals?

Achillion Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totalling 9,253,219 shares, a decrease of 11.9% from the April 28th total of 10,499,931 shares. Based on an average trading volume of 1,087,603 shares, the days-to-cover ratio is currently 8.5 days. Approximately 8.0% of the company's stock are short sold.

Who are some of Achillion Pharmaceuticals' key competitors?

Who owns Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include RA Capital Management LLC (9.97%), Vanguard Group Inc. (0.00%), Janus Capital Management LLC (3.21%), State Street Corp (3.16%), Morgan Stanley (0.00%) and Wellington Management Group LLP (0.00%). Company insiders that own Achillion Pharmaceuticals stock include David Apelian, Jason S Fisherman, Joel C Barrish, Mary Kay Fenton and Nicole Vitullo. View Institutional Ownership Trends for Achillion Pharmaceuticals.

Who sold Achillion Pharmaceuticals stock? Who is selling Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Morgan Stanley, Spark Investment Management LLC, Janus Capital Management LLC, Bellevue Group AG, Renaissance Technologies LLC, Tudor Investment Corp ET AL and UBS Group AG. View Insider Buying and Selling for Achillion Pharmaceuticals.

Who bought Achillion Pharmaceuticals stock? Who is buying Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Eventide Asset Management LLC, HealthInvest Partners AB, Stifel Financial Corp, Teachers Advisors LLC, Dimensional Fund Advisors LP, Credit Suisse AG and Cornerstone Capital Management Holdings LLC.. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Insider Buying and Selling for Achillion Pharmaceuticals.

How do I buy Achillion Pharmaceuticals stock?

Shares of Achillion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Achillion Pharmaceuticals stock cost?

One share of Achillion Pharmaceuticals stock can currently be purchased for approximately $4.14.

Analyst Ratings

Consensus Ratings for Achillion Pharmaceuticals (NASDAQ:ACHN) (?)
Ratings Breakdown: 2 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $9.75 (135.51% upside)

Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017Leerink SwannUpgradeMarket Perform -> Outperform$4.00 -> $6.00HighView Rating Details
4/26/2017Jefferies Group LLCReiterated RatingHoldLowView Rating Details
4/25/2017Maxim GroupLower Price TargetBuy$8.00 -> $5.00HighView Rating Details
4/24/2017Robert W. BairdBoost Price TargetOutperform$5.00 -> $10.00HighView Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$10.00N/AView Rating Details
11/4/2016Chardan CapitalUpgradeSell -> Neutral$5.00N/AView Rating Details
11/3/2016WedbushReiterated RatingOutperform$13.00N/AView Rating Details
9/15/2016FBR & CoInitiated CoverageOutperform$16.00N/AView Rating Details
7/7/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$13.00N/AView Rating Details
12/8/2015William BlairReiterated RatingOutperform$16.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Earnings by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Earnings History by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.16)($0.15)ViewN/AView Earnings Details
2/23/2017Q4 2016($0.18)($0.03)$15.00 millionViewN/AView Earnings Details
11/3/2016Q3($0.16)($0.15)ViewN/AView Earnings Details
8/4/2016Q2($0.15)($0.14)ViewN/AView Earnings Details
5/3/2016Q116($0.14)($0.13)ViewN/AView Earnings Details
2/25/2016Q4$0.09$0.12$31.40 million$31.60 millionViewN/AView Earnings Details
11/5/2015Q3$0.09$0.19$32.62 million$33.82 millionViewN/AView Earnings Details
8/10/2015Q2($0.18)($0.25)$0.71 millionViewN/AView Earnings Details
5/7/2015Q115($0.22)($0.17)ViewN/AView Earnings Details
3/5/2015Q414($0.19)($0.21)ViewN/AView Earnings Details
11/4/2014Q314($0.18)($0.16)ViewN/AView Earnings Details
8/7/2014Q214($0.18)($0.16)ViewN/AView Earnings Details
5/7/2014Q114($0.17)($0.17)ViewN/AView Earnings Details
3/7/2014Q413($0.16)($0.14)$0.01 millionViewN/AView Earnings Details
11/12/2013Q3($0.20)($0.14)ViewN/AView Earnings Details
5/7/2013Q113($0.15)($0.14)ViewN/AView Earnings Details
11/8/2012Q312($0.17)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)
2017 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.17)($0.16)($0.17)
Q2 20173($0.17)($0.17)($0.17)
Q3 20173($0.18)($0.18)($0.18)
Q4 20171($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)


Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Insider Ownership Percentage: 6.52%
Institutional Ownership Percentage: 77.85%
Insider Trades by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Insider Trades by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/22/2016Jason S FishermanDirectorBuy10,000$3.96$39,600.00View SEC Filing  
12/5/2016Mary Kay FentonCFOBuy2,500$4.11$10,275.00View SEC Filing  
12/2/2016Joel C BarrishInsiderBuy2,500$4.06$10,150.00View SEC Filing  
12/30/2015David ApelianinsiderSell10,000$10.50$105,000.00View SEC Filing  
12/28/2015Mary Kay FentonCFOSell43,500$10.08$438,480.00View SEC Filing  
11/11/2015Nicole VitulloDirectorSell550,000$10.17$5,593,500.00View SEC Filing  
9/25/2015Nicole VitulloDirectorSell9,310$8.22$76,528.20View SEC Filing  
1/23/2015Mary Kay FentonCFOSell13,125$16.00$210,000.00View SEC Filing  
1/21/2015Milind DeshpandeCEOSell100,000$15.00$1,500,000.00View SEC Filing  
9/30/2014Ra Capital Management, LlcInsiderSell1,332,014$10.20$13,586,542.80View SEC Filing  
9/29/2014Ra Capital Management, LlcInsiderSell221,014$10.96$2,422,313.44View SEC Filing  
9/26/2014Ra Capital Management, LlcMajor ShareholderSell2,372,915$11.17$26,505,460.55View SEC Filing  
9/25/2014Ra Capital Management, LlcMajor ShareholderSell497,986$11.05$5,502,745.30View SEC Filing  
9/24/2014Ra Capital Management, LlcMajor ShareholderSell1,204,929$11.27$13,579,549.83View SEC Filing  
9/23/2014Ra Capital Management, LlcMajor ShareholderSell2,595,071$11.29$29,298,351.59View SEC Filing  
9/2/2014Ra Capital Management, LlcMajor ShareholderSell835,293$11.63$9,714,457.59View SEC Filing  
8/27/2014Ra Capital Management, LlcMajor ShareholderSell2,711,352$11.33$30,719,618.16View SEC Filing  
8/26/2014Ra Capital Management, LlcMajor ShareholderSell2,112,867$11.35$23,981,040.45View SEC Filing  
8/25/2014Joseph TruittEVPSell25,000$10.82$270,500.00View SEC Filing  
8/25/2014Ra Capital Management, LlcMajor ShareholderSell331,396$10.96$3,632,100.16View SEC Filing  
8/18/2014Milind DeshpandeCEOSell216,624$10.00$2,166,240.00View SEC Filing  
8/18/2014Ra Capital Management, LlcMajor ShareholderSell4,235,000$9.53$40,359,550.00View SEC Filing  
8/15/2014Michael D KishbauchDirectorSell495,812$9.40$4,660,632.80View SEC Filing  
8/13/2014Gary E FrashierDirectorSell5,000$8.00$40,000.00View SEC Filing  
6/20/2014Ra Capital Management, LlcInsiderSell880,000$8.40$7,392,000.00View SEC Filing  
6/16/2014Gary E FrashierDirectorSell55,000$8.00$440,000.00View SEC Filing  
6/16/2014Joseph TruittEVPSell25,000$7.82$195,500.00View SEC Filing  
6/16/2014Qvt Associates Gp LlcMajor ShareholderSell1,819,551$7.70$14,010,542.70View SEC Filing  
6/11/2014Qvt Associates Gp LlcMajor ShareholderSell128,649$7.66$985,451.34View SEC Filing  
6/10/2014Joseph TruittEVPSell50,000$6.02$301,000.00View SEC Filing  
6/10/2014Michael D KishbauchDirectorSell371,937$7.75$2,882,511.75View SEC Filing  
12/30/2013Qvt Associates Gp Llcmajor shareholderSell170,239$3.34$568,598.26View SEC Filing  
12/26/2013Qvt Associates Gp Llcmajor shareholderSell121,205$3.44$416,945.20View SEC Filing  
12/23/2013Qvt Associates Gp Llcmajor shareholderSell289,141$3.24$936,816.84View SEC Filing  
12/19/2013Qvt Associates Gp Llcmajor shareholderSell222,612$3.09$687,871.08View SEC Filing  
12/17/2013Qvt Associates Gp Llcmajor shareholderSell92,803$3.11$288,617.33View SEC Filing  
11/22/2013Dennis LiottaDirectorBuy10,000$2.98$29,800.00View SEC Filing  
11/20/2013Ra Capital Management, LlcInsiderBuy1,110,000$2.55$2,830,500.00View SEC Filing  
11/19/2013Jason FishermanDirectorBuy15,000$2.63$39,450.00View SEC Filing  
11/12/2013Ra Capital Management, LlcInsiderBuy1,795,000$2.48$4,451,600.00View SEC Filing  
10/31/2013Ra Capital Management, LlcInsiderBuy1,186,007$2.45$2,905,717.15View SEC Filing  
10/14/2013Ra Capital Management, LlcInsiderBuy2,369,229$2.79$6,610,148.91View SEC Filing  
10/11/2013Ra Capital Management, LlcInsiderBuy2,448,710$2.56$6,268,697.60View SEC Filing  
9/30/2013Ra Capital Management, LlcInsiderBuy2,800,000$2.98$8,344,000.00View SEC Filing  
8/14/2013Jason FishermanDirectorBuy5,000$6.83$34,150.00View SEC Filing  
8/12/2013Dennis LiottaDirectorBuy5,000$6.47$32,350.00View SEC Filing  
8/9/2013Qvt Associates Gp Llcmajor shareholderBuy102,282$6.41$655,627.62View SEC Filing  
7/11/2013Qvt Associates Gp LlcMajor ShareholderBuy401,017$6.46$2,590,569.82View SEC Filing  
7/10/2013Qvt Associates Gp LlcMajor ShareholderBuy390,944$6.33$2,474,675.52View SEC Filing  
7/8/2013Qvt Associates Gp LlcMajor ShareholderBuy642,509$6.28$4,034,956.52View SEC Filing  
7/3/2013Qvt Associates Gp LlcMajor ShareholderBuy1,963,248$6.43$12,623,684.64View SEC Filing  
7/1/2013Gary E FrashierDirectorSell5,000$8.17$40,850.00View SEC Filing  
6/21/2013Jason S FishermanDirectorBuy10,000$7.63$76,300.00View SEC Filing  
6/7/2013Gary E FrashierDirectorSell5,000$8.37$41,850.00View SEC Filing  
6/3/2013Jason S FishermanDirectorBuy10,000$7.87$78,700.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Achillion Pharmaceuticals (NASDAQ:ACHN)
Latest Headlines for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateHeadline logoAchillion Pharmaceuticals, Inc. Forecasted to Earn FY2018 Earnings of ($0.28) Per Share (ACHN) - May 22 at 9:34 AM logoWhy Achillion Pharmaceuticals Stock Is Jumping 15% Today - May 18 at 3:16 PM logoAchillion: It Can't Get Any Worse…Or Can It? - May 18 at 12:34 PM logoAchillion Pharmaceuticals, Inc. (ACHN) Upgraded to "Outperform" by Leerink Swann - May 18 at 8:10 AM logoAchillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : May 11, 2017 - May 11 at 8:28 PM logoAchillion Pharmaceuticals, Inc. (ACHN) Downgraded by Zacks Investment Research to "Hold" - May 10 at 1:34 PM logoAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : May 10, 2017 - May 10 at 9:37 AM logoAchillion Pharmaceuticals, Inc. (ACHN) Expected to Post Earnings of -$0.17 Per Share - May 9 at 7:44 AM logoAchillion (ACHN) Reports Wider-than-Expected Loss in Q1 - May 8 at 3:16 PM logoAchillion Pharmaceuticals, Inc. Expected to Earn FY2019 Earnings of $0.38 Per Share (ACHN) - May 8 at 12:12 PM logoAchillion Pharmaceuticals, Inc. (ACHN) Issues Quarterly Earnings Results - May 5 at 3:58 PM logoAchillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs - May 4 at 3:17 PM logoAchillion reports 1Q loss - May 4 at 6:27 AM logoAchillion to Present at the Deutsche Bank 42nd Annual Health Care Conference - May 2 at 3:21 PM logoAchillion Pharmaceuticals (ACHN) Earning Favorable Media Coverage, Study Shows - May 2 at 7:52 AM logoAchillion Pharmaceuticals, Inc. (ACHN) Given Consensus Recommendation of "Buy" by Brokerages - May 1 at 12:02 PM logoAchillion Pharmaceuticals, Inc. (ACHN) Scheduled to Post Quarterly Earnings on Monday - April 29 at 1:30 AM logoAchillion Pharmaceuticals, Inc. (ACHN) to Release Quarterly Earnings on Monday - April 29 at 1:21 AM logoAchillion Pharmaceuticals, Inc. (ACHN) Set to Announce Earnings on Monday - April 29 at 1:20 AM logoAchillion Pharmaceuticals (ACHN) Earning Favorable News Coverage, Analysis Finds - April 27 at 2:04 PM logoAchillion Pharmaceuticals, Inc. (ACHN) Stock Rating Reaffirmed by Jefferies Group LLC - April 26 at 6:22 PM logoETFs with exposure to Achillion Pharmaceuticals, Inc. : April 25, 2017 - April 26 at 5:42 AM logoAchillion Pharmaceuticals, Inc. (ACHN) Rating Reiterated by Maxim Group - April 25 at 11:23 AM logoWhy Achillion Pharmaceuticals Stock Sank on Monday - April 25 at 9:27 AM logoAchillion Pharmaceuticals' (ACHN) Outperform Rating Reiterated at Robert W. Baird - April 24 at 4:42 PM logoAchillion Pharma (ACHN) Reports Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6 ... - - April 24 at 3:20 PM logoSomewhat Positive Press Coverage Very Likely to Affect Achillion Pharmaceuticals (ACHN) Share Price - April 24 at 11:47 AM logoAchillion Pharma (ACHN) Reports Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178 - April 24 at 11:16 AM logoAchillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178 - April 22 at 10:55 AM logoFavorable News Coverage Very Likely to Affect Achillion Pharmaceuticals (ACHN) Share Price - April 21 at 8:17 AM logoZacks: Analysts Anticipate Achillion Pharmaceuticals, Inc. (ACHN) to Post -$0.10 EPS - April 18 at 11:38 AM logoAchillion Pharmaceuticals (ACHN) Getting Positive News Coverage, Analysis Finds - April 17 at 10:07 AM logoSomewhat Positive Press Coverage Very Likely to Impact Achillion Pharmaceuticals (ACHN) Stock Price - April 13 at 1:28 PM logoAchillion Pharma (ACHN) to Initiate Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria - April 7 at 5:35 AM logoAchillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria - April 7 at 5:35 AM logoAchillion Pharmaceuticals, Inc. (ACHN) Sees Large Increase in Short Interest - April 4 at 3:21 PM logoToday's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and Corbus Pharmaceuticals - March 31 at 3:23 PM logoBiotech Stocks Under Scanner -- Celsion, Achillion Pharma, Tenax Therapeutics, and Cerulean Pharma - March 29 at 8:52 AM logoWhy Is Achillion (ACHN) Down 11.3% Since the Last Earnings Report? - Yahoo Finance - March 28 at 3:17 PM logoTheStreet Downgrades Achillion Pharmaceuticals, Inc. (ACHN) to D - March 26 at 11:43 PM logoAchillion Pharma (ACHN) Granted USPTO Matter Patent for Small Molecule Complement Alternative Pathway Factor D Inhibitors - March 22 at 1:37 AM logoAfter-Hours Stock Movers 03/21: (DLTH) (SLW) (FDX) Higher; (RGNX) (ADAP) (NKE) Lower (more...) - March 21 at 8:35 PM logoUSPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors - March 21 at 8:35 PM logoAchillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2017 - March 17 at 8:29 PM logoThese 5 Stocks Under $10 Could Explode Up Soon - March 2 at 3:19 PM logoAerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect? - March 1 at 8:18 PM logoACHILLION PHARMACEUTICALS INC Financials - March 1 at 3:16 PM logoAchillion Pharmaceuticals to Support a Natural History Study of C3 ... - February 28 at 3:19 PM logoAchillion Pharma (ACHN) to Support Natural History Study of C3 Glomerulopathy - - February 28 at 7:19 AM logoAchillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London - February 28 at 7:19 AM



Achillion Pharmaceuticals (ACHN) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff